Tetherex

Tetherex Pharmaceuticals Corp is a clinical-stage development biopharmaceutical company focused on development of therapeutics for the treatment of inflammation, thrombosis and tumor metastasis across a broad range of severe diseases. Its lead program is built around an antibody called SelK2 directed against the cell adhesion molecule P-Selectin Glycoprotein Ligand-1 (PSGL-1). SelK2 is currently under clinical development in a Phase 1 clinical study for Crohn's disease.